Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, held its Annual General Meeting today during which the Company’s Management presented an overview of its activities and challenges in 2018 along with an outlook for 2019.
During the meeting, Julphar’s Chairman Sheikh Saqr Bin Humaid Al Qasimi and CEO Jerome Carle addressed shareholders who reviewed and approved the Company’s financial statements for 2018. They also discussed and approved the appointment of new external auditors and the ratification of two new board members.
Carle said: “While 2018 has been a very difficult year for the company, we were encouraged by how our leadership team and the organization as a whole responded to the challenges that surfaced during the year.
“The Company’s prudent long-term growth plans have enabled it to remain resilient despite challenges in the business environment. We remain committed to the targets that we outlined in our long-term plan and we will be proactive in managing costs and investment to meet any future challenges.
During 2018, Julphar’s revenue was negatively impacted by product recalls and the Saudi Food & Drug Authority’s temporary ban on the export of the company’s products to the Kingdom. Julphar also faced some challenges related to legacy issues and across MENA markets, including currency devaluation and political turmoil. Consequently, the company’s management has focused on cost reductions and has taken several actions to strengthen the organization and maximize cash flows.
“In 2019, with our new Board members and recently appointed new Management Team, we are bringing in new skills and capabilities, we are launching innovative products in key markets, we are implementing a new Quality Management System and we are working with some of the world’s leading organizations to help advance the Company’s new global strategy.
“Julphar is well-placed to navigate the risks inherent in today’s world and the long-term drivers of revenue growth remain sound. We will continue to steer ahead with our vision to reinvigorate the Company for the future to ensure we are able to deliver positive value to our Shareholders.”
Julphar’s Board of Directors expressed their appreciation to all customers and suppliers for their ongoing support of Julphar’s activities. They also extended their appreciation to all partners, shareholders, management and employees for their efforts and continued dedication.
-Ends-
About Julphar
Julphar is one of the largest pharmaceutical manufacturers in the Middle East and Africa and for almost four decades, the company has been delivering high quality, innovative and affordable healthcare solutions to families across the globe. Established under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi in 1980, Julphar employs more than 5,000 people and distributes pharmaceutical products to 50 countries on five continents.
Julphar’s business is centered on three core business units – Julphar Diabetes Solutions, General Medicines and its consumer division, Julphar Life – which target major therapeutic segments including Gastrology, Pain Management, Wound Care, Antibiotics and Cardio-metabolism. Julphar has 16 internationally accredited facilities in Africa, Middle East and Asia that produce more than a million boxes of medicine a day. In 2012, Julphar became one of the largest producers of insulin in the world.
For more information, visit http://www.julphar.net
For media enquiries, please contact:
Chris Goward
Julphar
Corporate Communications
T +971 7 246 1461 | M +971 58 263 3997
Email: chris.goward@julphar.net
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
